Solid Biosciences (SLDB) Times Interest Earned (2023 - 2025)
Solid Biosciences (SLDB) posted Times Interest Earned of -$10.55 for Q1 2026, up 6.36% sequentially from -$11.27 in Q4 2025, and up 96.31% YoY from -$5.38 in Q1 2025.
Analysis
Solid Biosciences (SLDB) Times Interest Earned (2023 - 2025) Analysis & Trends
Solid Biosciences has reported Times Interest Earned for 10 years, with the latest figure at -$10.55 in Q1 2026.
- Quarterly Times Interest Earned rose 96.31% year-over-year to -$10.55 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$36.17 (up 96.46% YoY) and the FY2025 annual result came in at -$0.94, up 5.2% from the prior year.
- Times Interest Earned rose to -$10.55 in Q1 2026 per SLDB's latest filing, from -$11.27 in the prior quarter.
- Over five years, Times Interest Earned peaked at -$0.21 in Q4 2022 and troughed at -$497.49 in Q1 2022.
- A 5-year average of -$176.93 and a median of -$208.05 in 2022 frame the typical range for Times Interest Earned.
- The sharpest annual moves came in 2023 and 2026: Times Interest Earned sank 2431.42% in 2023, then jumped 96.31% in 2026.
- Over 5 years, Times Interest Earned stood at -$0.21 in 2022, then tumbled by 2431.42% to -$5.35 in 2023, then plunged by 86.49% to -$9.98 in 2024, then declined by 12.95% to -$11.27 in 2025, then climbed by 6.36% to -$10.55 in 2026.
- According to Business Quant data, Times Interest Earned over the past three periods registered -$10.55, -$11.27, and -$29.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -493.00 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -21.24 |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 8.18 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 2.82 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 1.42 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.08 |
| 10 | Solid Biosciences | 1.48 Bn | 1.48 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -9,880.60 |
| Sep 30, 2025 | 143.03 |
| Jun 30, 2025 | -694.88 |
| Mar 31, 2025 | -589.00 |
| Dec 31, 2024 | -531.95 |
| Sep 30, 2024 | -429.05 |
| Jun 30, 2024 | -315.77 |
| Mar 31, 2024 | -282.76 |
| Dec 31, 2023 | -220.45 |
| Sep 30, 2023 | -218.06 |
| Jun 30, 2023 | -241.83 |
| Mar 31, 2023 | -264.71 |